<i>In vivo</i> Hyperspectral Imaging of Microvessel Response to Trastuzumab Treatment in Breast Cancer Xenografts
HER2-amplified (HER2+) breast cancers are treated with the anti-HER2 monoclonal antibody trastuzumab. Although trastuzumab reduces production of the angiogenic factor VEGF in HER2+ tumors, the acute and sustained effects of trastuzumab on the tumor vasculature are not understood fully in trastuzumab...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en |
| Published: |
VANDERBILT
2014
|
| Subjects: | |
| Online Access: | http://etd.library.vanderbilt.edu/available/etd-06162014-101705/ |